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Objectives: Marine v-3 fatty acids (FAs) and Vitamin D (VitD) are reportedly capable of down-regulating
inflammation in rheumatoid arthritis (RA) and periodontal disease. This study was undertaken to relate
marine FA and VitD status to RA disease status and periodontal conditions.
Methods: RA outpatients (age 35 y) were consecutively recruited. Rheumatologic clinical data were col-
lected and periodontal status obtained. A food frequency questionnaire was used to estimate fish and sup-
plement intake. FA profiles in whole-blood and serum VitD levels were determined.
Results: A total of 78 RA patients (age 57§12 y, disease duration 15§11 y) were included, 58% had active
RA. Periodontitis was diagnosed in 82% of the patients, 18% had severe periodontitis. Seropositivity for rheu-
matoid factor and/or anticitrullinated protein antibodies was related to higher prevalence of periodontitis
(P =0.008). Seafood intake in accordance with nutritional recommendations was associated with better RA
disease outcome (largest P =0.008). An v-3 index >8, present in 14% of the patients, correlated with a more
desirable patient global health assessment scored on a visual analog scale (VAS; P =0.004), lower periodon-
tal probing depth (PD; P =0.021), and v-3 supplementation (P =0.001). Serum VitD levels >50nmol/L were
found in 89%, of these 48% had VitD levels 75nmol/L, no differences were found for RA disease activity
and periodontal measurements.
Conclusions: Seropositive RA patients had a higher prevalence of periodontitis than seronegative patients.
An v-3 index >8 was related to v-3 supplementation and more desirable VAS and lower PD. VitD status
was satisfactory for most patients and was not associated with differences in RA severity or periodontal
diagnosis.
© 2018 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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Rheumatoid arthritis (RA) and periodontitis are chronic pro-
gressive inflammatory diseases associated with soft and hard tis-
sue destruction. Genetic, epigenetic, and environmental factors
drive host responses in both diseases [13]. An association
between periodontitis and RA has been described in systematic
reviews [4] and meta-analyses [5]. The etiopathogenesis of RA is
complex and the offending stimulus is still not clear. It ishypothesized that a second inflammatory “hit” is required to stim-
ulate development of the disease [6]. Translocation and trapping
of oral bacterial DNA from inflamed periodontal tissue into syno-
vial fluid suggest the involvement of periodontitis in the etiopa-
thogenesis of RA [7]. Although periodontal disease is clearly
initiated by bacteria, the underlying mechanisms are hyperactive
immune responses of the host to dysbiotic bacterial infection [8].
Periodontitis is a major cause of tooth loss in adults, which can
exert a negative impact on nutritional status and health-related
quality of life (HRQOL) [9]. In active RA, systemic inflammation is
associated with multiple extraarticular comorbidities such as
depression, asthma, cardiovascular events, malignancies, and
chronic obstructive pulmonary disease, resulting in a significant
reduction in HRQOL [10,11].
Not meeting inclusion criteria ( = 11)
Ethnicity ( = 3), Age < 35 years ( = 5),
Diabetes ( = 3)
Clinical medical examination
Clinical dental examination ( = 89)
Clinical data on RA and periodontal status
Questionnaires: FFQ
Laboratory analyses: PUFA, s-25(OH)D
Assessed for eligibility ( = 140)
Excluded ( = 51)
Declined participation ( = 26)
Discontinued (compliance) ( = 25)
Analyses ( = 78)
Fig. 1. Patient flow chart. FFQ, food frequency questionnaire; PUFA, polyunsatu-
rated fatty acid; RA, rheumatoid arthritis; s-25(OH)D, serum levels of 25-hydroxy-
vitamin D.
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blood lipids reflects dietary fat intake and relate to health status
[12,13]. Polyunsaturated FAs (PUFAs) in the v-3 series and v-6
series are precursors to potent lipid mediator signaling molecules,
which have important roles in immune regulation and inflamma-
tion [14]. Marine v-3 PUFAs are capable of down-regulating
inflammation in RA and periodontitis [15,16]. In most populations,
intake of v-6 PUFA is increased, whereas the consumption of v-3
PUFA is either insufficient or not effective at providing adequate
tissue levels of the v-3 PUFA eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) [13].
Vitamin D (VitD) might affect RA and periodontal disease
through immunomodulatory effects. The active metabolite
1,25dihydroxyvitamin D3 was found to downregulate pro-
inflammatory mediators such as TNF-a and RANKL in monocyte-
derived macrophages from peripheral blood of RA patients [17]
and to be inversely associated with severity of periodontitis in
non-RA patients [18]. In RA patients, serum 25-hydroxyvitamin D
(s-25[OH]D) levels were reduced and showed an inverse relation-
ship with RA disease activity, interleukin (IL)-17/IL-23, and bone
loss [19]. Whereas a higher VitD intake corresponded to lower
odds of severe periodontal disease, moderate-to-severe alveolar
bone loss has been linked to lower VitD intake [20], and insuffi-
cient VitD status has been related to decreased clinical periodontal
attachment gain following periodontal surgery [21]. Genetic poly-
morphisms of the VitD receptor gene have also been related to
severity of RA and chronic periodontitis [22,23], and enrichment
of VitD response elements at RA-associated loci supports a role for
VitD in development of this disease [24].
The aim of the present study was to examine the association
between RA disease status and periodontal conditions in relation
to intake and status of marine v-3 FA and VitD.
Methods
Ethics
Study protocol and informed written consent of all partici-
pants, according to the Helsinki Declaration of 1975, version 2008
[25], were approved by the Institutional Medical Research Ethics
Committee (2012/2212), University of Bergen, Norway.
Study design and patient selection
The data for this cross-sectional study were collected between
May 2013 and March 2016 at the Department of Rheumatology at
Haukeland University Hospital and at the Department of Clinical
Dentistry at the University of Bergen (Bergen, Norway). A patient
flow chart is presented in Figure 1. RA outpatients with chronic
established RA were invited to participate (N =140). RA disease
was classified using the 2010 classification criteria of American
College of Rheumatology/European League Against Rheumatism
(ACR/EULAR) [26]. Inclusion criteria were chronic established RA,
Caucasian ethnicity, and 35 y of age. Exclusion criteria were dia-
betes, malignancy, pregnancy, breast-feeding, and antibiotic use
within 3mo before the study. Demographic and behavioral char-
acteristics were collected using questionnaires. Past medical his-
tory, clinical, and laboratory data on RA status and medication
were obtained frommedical records.
Assessment of RA disease activity
Recorded data included disease duration of RA, disease activity
score (DAS28) [27,28], joint damage, modified health assessmentquestionnaire (MHAQ) [29], and a patient global health assess-
ment scored on a visual analog scale (VAS). Routine laboratory
analyses included erythrocyte sedimentation rate (ESR), C-reac-
tive protein (CRP), rheumatoid factor (RF), and/or anticyclic citrul-
linated peptides (anti-CCP) titers. Based on the laboratory
reference level, all values >25 IU/mL for RF and 3U/mL for
anticitrullinated protein antibodies (ACPAs) were classified as
seropositive for autoantibodies. VAS was measured on a horizon-
tal visual analog scale of 10 cm with “no pain” at one end and
“worst possible pain” at the other end. The patient was instructed
to mark “X” on the scale by using the following phrasing: “We
kindly ask you to review the activity of your rheumatic disease
during the last week. When you take all the symptoms into
account, how do you rate your condition?”. RA disease activity
score (DAS28) was calculated using tender 28 joint score, swollen
28 joint score, ESR, and VAS. Active RA was defined as DAS28 2.6
and remission as DAS28 <2.6 [30]. Low disease activity was con-
firmed if DAS28 score was 3.2, moderate if DAS28 score was
>3.2 to 5.1, and high if DAS28 score was >5.1 [31].
Disease modifying antirheumatic drugs (DMARDs) were
grouped as follows: Conventional DMARDs (methotrexate, leflu-
nomide, hydroxychloroquine, sulfasalazine), biological DMARDs
(tumor necrosis factor [TNF]-inhibitors, B-cell inhibitors, IL-6
inhibitors), and a combination of conventional and biological
DMARDs.
Clinical oral examination
Clinical oral examination and periodontal data collection were
performed under standardized conditions by a single dentist (K.
B.). Detailed description is provided in Supplementary Methods.
Prior to the study, calibration training for intraexaminer (K.B.)
reproducibility of periodontal registrations was conducted. The
intraclass correlation coefficient (ICC) ranged between 0.83 and
0.91 for probing depth (PD) and between 0.93 and 0.98 for clinical
attachment level (CAL).
A comprehensive periodontal examination including registra-
tion of PD, CAL, bleeding on probing (BoP), and accumulation of
bacterial plaque (plaque index, PI) was assessed at six sites per
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Chicago, Ilinois, USA). Third molar, if not in position of second
molar, was excluded from periodontal registration.Assessment of periodontal status
The periodontal status assessment was adapted from the Cen-
ters for Disease Control-American Academy of Periodontology
clinical case definitions with some modifications [32]. Subjects
were classified into three subgroups: 1) gingivitis: PD 3mm, and
BoP; 2) mild/moderate periodontitis:2 interproximal sites with
CAL 3mm (not on the same tooth) and 2 interproximal sites
with PD 4 (not on the same tooth) and BoP; or 3) severe peri-
odontitis:2 interproximal sites with CAL 6mm (not on the
same tooth) and 1 interproximal site with PD 5mm and BoP.Smoking status
Current smokers were defined as subjects who smoked at the
time of study enrollment. Former smokers were subjects who had
stopped smoking. The number of pack-years was calculated by
dividing the number of cigarettes smoked per day by 20 and mul-
tiplying by the number of years smoked.Assessment of seafood intake and dietary supplement intake
RA patients completed a validated, short version food fre-
quency questionnaire (FFQ), described in detail by Dahl et al. [33].
In brief, semiquantitative and retrospective habitual intake of sea-
food for dinner, as sandwich spread, in salads, or as snack meal
during the last three months was investigated. Additionally, self-
reported information about physical activity and sun exposure
habits were registered. The FFQ was analyzed as described by
Markhus et al. [34]. To compute the patients' total seafood index,
composed of the seafood dinner index, seafood spread index, and
v-3 supplement index, the frequency data of the participants'
indices were converted into numerical values. Adaptions to Mar-
khus et al. [34] were made regarding the frequencies for total din-
ner seafood index as follows: “once a week” was converted to the
numerical value 1, “two to three times per week” set to value 2.5,
and “four or more times per week”was set to value 4. For the total
seafood spread index, the frequencies were converted as follows:
“three to five times per week” was set to the numerical value 4
and “more than five times per week” was set to value 5. The range
of the total seafood index was 0 to 14. A standard Norwegian din-
ner seafood portion is defined as 150g (e.g., one slice of salmon fil-
let, three fishcakes, or 2 dL of shrimp) [35]. According to the
Norwegian food recommendations, 300 to 450g/wk of fish for
dinner and spread (fish filet and processed fish products) should
be part of a healthy balanced diet, of which at least 200 g should
be oily fish [36]. The total fish intake per week (including fish filet,
fish as spread, and processed fish) corresponds to 54g/d of raw
fish and 35g/d for oily fish [37].
The FFQ also provided information about the use of supple-
ments (marine v-3, VitD, and calcium) during the last 3mo. For
v-3 supplement, product names, amount (capsules or spoons),
and frequency of supplement intake were recorded. Seasonal vari-
ation inv-3 supplement intake during the year was registered.
The questionnaire was designed to be self-instructive; how-
ever, assistance was provided in case of item non-response.Blood collection
Peripheral venous blood samples were obtained by venipunc-
ture at the antecubital fossa (Vacutainer Blood Collection Set, BD
Vacutainer, Becton, Dickinson and Company, Franklin Lakes, New
Jersey).Laboratory analyses
For analysis of s-25(OH)D levels, 4mL venous blood was col-
lected in Serum Sep Clot Activator vacutainers (Greiner Bio-One
Gmbh, Kremsmuenster, Austria) and set to coagulate for mini-
mum 30min (maximum 60min). After centrifugation at 1300£
g for 10min, the supernatant was stored at ¡80°C until analysis.
S-25(OH)D was determined by isotope dilution liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS) at the Hormone
Laboratory at Haukeland University Hospital, Bergen, Norway
[38]. S-25(OH)D levels were measured as sum of ergocalciferol
(25[OH]D2) and cholecalciferol (25[OH]D3), whereas 25(OH)D2
was found to be below the limit of quantification (LOQ). VitD sta-
tus was evaluated as follows: Deficiency <20ng/mL (<50nmol/L),
insufficiency 20 to 30ng/mL (5075nmol/L), and sufficiency
>30ng/mL (>75nmol/L) [39,40]; or deficiency <12ng/mL (<30
nmol/L), insufficiency 12 to 20ng/mL (3050nmol/L), and suffi-
ciency >20ng/mL [41].
Whole-blood samples for analysis of FA were collected in 3mL
EDTA vacutainers (Greiner Bio-One Gmbh, Kremsmuenster, Aus-
tria) and analyzed at Institute of Marine Research, Bergen, Nor-
way, using ultrafast gas chromatography (UFGC) as an accredited
laboratory method (NS-EN ISO/IEC 17025). The FA composition
was calculated using an integrator (Chromeleon 6.80, Dionex Cor-
poration, California) connected to the UFGC. The limit of quantifi-
cation (LOQ) was 0.01, values <0.1 were recoded to the half of
LOQ. Results were expressed as percentage of total FA by sum-
ming the absolute values of all analyzed FAs and dividing each FA
by this value.Evaluation of v-3 FA status
The v-3 index was used to evaluate v-3 FA status and is
defined as the sum of EPA and DHA, expressed as percentage of
total FA [42].Statistical analyses
Median and range were calculated for continuous variables.
The Shapiro-Wilk test for normality was used to test for normality
with a critical alpha value of 5%. The Wilcoxon rank-sum test was
applied for continuous variables not normally distributed. Student
t test (for continuous variables) and Pearson chi-square (for cate-
gorical variables) were used to test for differences between the
groups. For the site-specific measures of PD and CAL, taken at
each site for all teeth for each patient, mixed effect models with a
random effect for patient and tooth were performed. For the rela-
tion between RA disease activity and the site-specific measures,
logistic regression models with robust variance estimates adjust-
ing for the clustering of tooth within patients were performed. A P
value<0.05 was considered statistically significant. All statistical
data analysis was performed using the statistical software STATA
version 14.0 for Microsoft Windows (StataCorp LP, Texas).
Table 2
Continuous variables, clinical characteristics of all rheumatoid arthritis patients
and grouped by disease activity (N =78)
Total Remission Active RA P value
N=78 N=35 N=43
Age (y) 57.1§11.5 56.5§11.6 57.5§11.6 0.70
BMI (kg/m2) 26.1§4.3 25.9§4.4 26.3§4.4 0.63*
Oral data
Teeth, n 25§5 25§4 24§6 0.22
PD (mm) 2.8§0.4 2.7§0.3 2.8§0.4 0.65
CAL (mm) 3.1§0.8 3.0§0.7 3.1§0.8 0.57
BoP (% of sites) 31§16 33§14 30§17 0.49
PI (% of sites) 33§16 36§19 31§14 0.20
RA data
RA debut (age) 43§14 41§13 45§15 0.30
RA duration (y) 15§11 16§12 14§11 0.37*
DAS28 (score) 3.0§1.1 2.1§0.3 3.7§1.0 <0.001*
VAS (score) 28§21 17§14 36§21 <0.001*
MHAQ (score) 0.37§0.38 0.17§0.25 0.52§0.39 <0.001*
Laboratory data
ESR (mm/h) 19.8§15.5 12.7§8.3 25.0§17.5 <0.001*
CRP (mg/L) 8.8§13.5 5.0§10.0 11.6§15.1 0.001*
S- 25(OH)D (nmol/L) 74§19 78§19 71§19 0.071
Supplementation
Vitamin D (mg/d)y 27§12 30§13 25§12 0.25*
BMI, body mass index; BoP, bleeding on probing; CAL, clinical attachment level;
CRP, C-reactive protein; DAS28, disease activity score 28; ESR, erythrocyte sedi-
mentation rate; MHAQ, modified health assessment questionnaire; PD, probing
depth; PI, plaque index; RA, rheumatoid arthritis; s-25(OH)D, 25-hydroxy vitamin
D; VAS, visual analog scale.
Values reported as mean§ standard deviation.
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The study population consisted of 78 RA patients (58% with
active RA disease), ages 57 y (range 35.177.6 y). Categorical vari-
ables, behavioral and clinical characteristics, grouped by RA dis-
ease activity, are summarized in Table 1. Continuous variables and
clinical characteristics, also grouped by RA disease activity, are
summarized in Table 2. A description of the study subjects by sex
is presented in Supplementary Tables S1 for categorical variables
and Table S2 for continuous variables.
RA status
Active RA with low, moderate, or high disease activity (DAS28)
was found in 23 (30%), 17 (22%), and 5 (6%) patients, respectively.
In relation to disease duration, DAS28 differed in neither active RA
nor remission (P =0.51). Patients with active RA had significantly
elevated clinical and laboratory parameters related to RA disease
than patients in remission (P<0.001, Table 2). Of note, 54% (N =
22) of the RF positive patients and 30% (N = 10, P = 0.044) of the RF
negative patients were in RA disease remission. Prednisolone
treatment (mean dose 7.4mg/d, range 2.530), was found in a
higher number of patients with active RA disease (N =17, 38%)
than in RA patients with remission (N =4, 12%; P =0.012); no dif-
ferences were found for DMARDs.
Regarding the relation of smoking on RA disease activity, no
differences were found between active disease and remissionTable 1
Categorical variables and behavioral and clinical characteristics in RA patients,
grouped by disease activity (N=78)
Remission
(N=33)
Active RA
(N=45)
P value
n (%) n (%)
Females 24 (73) 33 (73) 0.95
Smoking status
Never smokers 12 (36) 17 (38) 0.74
Former smokers 17 (52) 20 (44)
Current smokers 4 (12) 8 (18)
Periodontal conditions
Gingivitis 5 (15) 9 (20) 0.68
Mild/moderate periodontitis 23 (70) 27 (60)
Severe periodontitis 5 (15) 9 (20)
Medical data on RA disease
Seropositive 28 (85) 32 (71) 0.16
Seropositivity for IgM-RF 22 (67) 19 (42) 0.044
Seropositivity for ACPAs 26 (79) 29 (64) 0.11
Joint destruction 19 (58) 22 (49) 0.45
Antirheumatic medication 31 (94) 43 (96) 0.45
Conventional DMARDs 13 (39) 20 (44)
Biological DMARDs 7 (21) 4 (9)
Combination conventional and
biological DMARDs
11 (33) 19 (42)
Prednisolone 4 (12) 17 (38) 0.012
Other medication
Oral bisphosphonates 3 (9) 5 (11) 0.77
Folic acid 19 (58) 28 (62) 0.68
Calcium 10 (30) 22 (49) 0.10
Supplements
v-3 17 (52) 26 (58) 0.58
Vitamin D 15 (45) 28 (62) 0.14
ACPA, anticitrullinated protein antibody; DAS28, disease activity score 28;
DMARDs, disease-modifying antirheumatic drugs; RA, rheumatoid arthritis; RF,
rheumatoid factor.
Values reported as number and percentage of patients. RA disease activity, diag-
nosed by DAS28; seropositive, positive tests for RF (N =74) and/or ACPA (N=77).
Analyzed with Pearson chi-square.
Analyzed with Student t test.
*Analyzed with Wilcoxon rank-sum.
yVitamin D users only (N = 45).(P = 0.74; Table 1). In current smokers, the mean smoking pack-
years were 14 y (range 530 y). Differences in smoking status
were found in ACPA seropositive patients compared with seroneg-
ative patients (P =0.049). A higher proportion of ACPA seropositive
(N=23, 42%) than seronegative patients (N=6, 27%) were never
smokers and more seronegative patients were current smokers
(N=7, 32%) compared with seropositive patients (N =5, 9%;
P = 0.043). Smoking status did not differ in RF seropositive patients
(P = 0.63).
Periodontal status
Gingivitis was diagnosed in 18%, mild to moderate periodonti-
tis in 64%, and severe periodontitis in 18% of the patients. Peri-
odontal disease status worsened with increased age (P =0.008).
The mean ages of patients with gingivitis, mild to moderate, or
severe periodontitis were 51, 58, and 63 y, respectively. For the
severity of periodontal disease, significant differences for PD
(P<0.001), CAL (P<0.001), BoP (largest P =0.033), and PI (largest
P =0.010) were found (Supplementary Table S3). Periodontitis was
found in a higher number of patients who tested seropositive for
RF and/or ACPA (N =53, 88%) compared with seronegative patients
(N =11, 61%; P =0.008).
At patient level for PD and CAL, respectively, a median (range)
of 3mm (110mm) and 3mm (114mm) was found. At tooth
level, mandibular molars had the highest mean PD (3.3mm) and
mean CAL (3.6mm). Mandibular incisors (PD 2.4mm, CAL 2.7mm)
and premolars (PD 2.5mm, CAL 3.0mm) had a lower PD/CAL com-
pared with their respective maxillary teeth (PD 2.6mm, CAL
2.8mm; and PD 2.8mm, CAL 3.2mm, respectively). Compared
with mandibular incisors, all other tooth types in both jaws had
significantly deeper PD (P<0.001) and CAL (P<0.001).
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(90% and 83%, respectively). Sites with PD and CAL of 4mm were
found in 7% and 9.5%, and PD and CAL 5mm were found in 3%
and 7.5%, respectively.
Dichotomizing study subjects by remission and active RA dis-
ease (DAS28 <2.6 or DAS28 2.6), no differences in PD, CAL, BoP,
PI at site level, or number of missing teeth were found (highest
P =0.11). Patients diagnosed with active RA and periodontitis
(N =36) had a higher mean CRP (12.9§16.4) and ESR (26.5§18.0)
compared with RA patients in remission having periodontitis
(N =28; CRP 5.4§10.8, P =0.043 and ESR 12.6§8.6, P<0.001). In
patients without periodontitis, no differences were found
between active RA and remission for CRP (P =0.13) and ESR
(P = 0.48).
Concerning the effect of smoking on PD and CAL, ever smokers
had higher mean PD (2.9§0.4mm) and mean CAL (3.2§0.9mm)
compared with never smokers (PD 2.6§0.2mm, P =0.002 and
CAL 2.8§0.3mm, P =0.015); no difference was found between
active RA and remission RA. With regard to sex, males who were
ever smokers had a higher mean PD (3.2§0.6mm) and CAL
(4.0§1.4mm) compared with females (PD 2.8§0.1mm, P =0.005
and CAL 2.9§0.4mm, P<0.001). Moreover, male sex and smoking
were associated with higher prevalence and more severe peri-
odontitis (P =0.037), fewer teeth (P<0.001), and more dental pla-
que (P =0.017) compared with female sex in ever smokers.
Between former and current smokers, no differences were found.Food frequency questionnaire
All patients reported seafood consumption as dinner, and 96%
reported seafood as spread. The frequency of seafood intake as
dinner and as spread, the number of portions as dinner, and the
corresponding amount of seafood intake in grams per day are pre-
sented in Table 3.Table 3
Frequency, number of portions, and estimated intake of seafood in RA patients, and grou
Total (N= 78) Females (N=57) Males (N =2
Seafood for dinner
Never 0 0 0
<1 time/mo 2 2 0
1 to 3 times/mo 3 1 2
1 time/wk 28 21 7
2 to 3 times/wk 43 32 11
4 times/wk 2 1 1
Portion size of dinner
0.5 portion 3 3 0
1 portion 45 38 7
1.5 portions 22 13 9
2 portions 8 3 5
3 portions 0 0 0
Seafood as spread
Never 3 3 0
<1 time/mo 13 9 4
1 to 3 times/mo 25 19 6
1 to 2 times/wk 24 16 8
3 to 5 times/wk 10 7 3
>5 times/wk 3 3 0
Seafood intake (g/d)
Total seafood 52§47 50§52 57§29
Dinner seafood 47§44 46§49 53§28
Oily fish 18§22 18§24 19§15
Intermediate/lean fish 17§20 18§20 22§18
RA, rheumatoid arthritis.
Values reported as number of patients and mean§ standard deviation. Portion size =150
Analyzed with Pearson chi-square.
*Analyzed with Wilcoxon rank-sum.The mean intake of seafood as dinner was 1.9§0.9 meals per
week. The consumption of seafood as a spread, such as on a sand-
wich, in a salad, or as a snack, was 1.4§1.4 meals per week. A sea-
food intake as dinner with 2 to 3 servings per week and a meal
size corresponding to the standard Norwegian seafood meal size
or higher was found in 45 patients (58%). Of them, 27 (60%)
reported 1 to 2 weekly serving with oily fish as dinner. The rela-
tive amount of seafood meals as dinner per week was 38% oily
fish, 32% lean fish, 16% manufactured fish product, 5% intermedi-
ate oily fish and shellfish each, and <5% fresh water fish and sushi.
Regarding RA disease severity, females consuming two or more
fish meals per week (N =33) were found to have lower mean
MHAQ (0.26) and VAS (22.6) compared with females having a
lower fish intake (N =24, MHAQ 0.51, P =0.008 and VAS 38.4,
P =0.003). No differences were found in males (MHAQ: P =0.59;
VAS: P = 0.22).
Elderly patients (N =44, >60 y of age) had higher median total
seafood intake (64 § 57g/d, range 13345) than younger patients
(N = 34, 60 y of age, 43 § 35 g/d, range 1213; P = 0.009).
Fish consumption of 54g/d for dinner was found in 31% of the
patients (89§59 g/d, range 55331). Between sex, fish consump-
tion 54g/d for dinner was found in 53% of the males (74§16g/
d, range 57107) and 23% of the females (102§79g/d, range
55331g/d; P =0.27), whereas 34g/d oily fish for dinner was
consumed by 14% (43§0 g/d, range 4343) and 5% (107§37g/d,
range 64129; P =0.040) of males and females, respectively.
Use of marine v-3 supplement was reported by 43 patients
(55%); of them, 19 (44%) took marine v-3 supplements only dur-
ing wintertime (mean 5.3mo). The mean intake was 3.9§2 times
per week. At the time of examination, 37 (86%) were using an v-3
supplement. No differences in use of marine v-3 supplements for
RA disease status and periodontal conditions were found.
Intake of cholecalciferol (VitD3) supplement from v-3 and/or
calcium supplement was reported by 43 patients (Tables 1 and 2).
VitD3 originating from v-3 supplement (17§6mg/d) wasped by sex and RA disease activity (N=78)
1) P value Remission (N=33) Active RA (N=45) P value
0 0
0.44 2 0 0.31
2 1
9 19
19 24
1 1
0.010 2 1 0.32
22 23
7 15
2 6
0 0
2 1
0.71 6 7 0.91
11 14
10 14
3 7
1 2
0.067* 42§30 60§55 0.063*
0.058* 37§28 54§53 0.045*
0.23* 12§11 22§27 0.030*
0.24* 16§15 21§22 0.32*
g.
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calcium supplement was 20§5mg/d. No differences for high or
low ultraviolet light exposure regarding RA disease activity or
between sex were found.
VitD3 users had higher s-25(OH)D levels (78§17nmol/L) com-
pared with non-users (68§20nmol/L, P =0.021). VitD3 users hav-
ing oily fish for dinner 1 to 2 times per week had higher s-25
(OH)D levels (80§18nmol/L) compared with VitD3 non-users
having less oily fish (63§15nmol/L, P =0.009). A s-25(OH)D<50
nmol/L was found in females, only (N=6, 42§7nmol/L), five of
six were not using VitD3.
There were no differences for s-25(OH)D between remission
and active RA disease (Table 2), periodontal diagnosis (data not
shown), nor sex (supplementary Table S2).Table 5
v-3 index in relation to selected whole-blood FAs, total seafood intake, and clinical
parameters on periodontal conditions and RA (N=78)
v-3 index v-3 index v-3 index
<4 4 to 8 >8
N=9 (12%) N=58 (74%) N=11 (14%)
Age (y) 48§12 57§11 64§9
FAs (wt%)
v-3 index 36§0.3 5.9§1.2 A 10.2§1.1 B,C
Sum v-6 FA 31.8§2.6 30.8§2.3 28.8§2.4 B,C
CFAs andv-3 index
The relative weight percentage of selected whole blood FA in
all patients and grouped by RA disease activity are presented in
Table 4. Selected whole blood FA (wt%), grouped by sex, and
according to the use and no use of marine v-3 supplement are
presented in Supplementary Table S4.
The mean v-3 index was 6.2§2.1 (range 312). The majority
of the study population had an v-3 index from 4 to 8, 14% had
an v-3 index >8, and 12% had an v-3 index <4. Older age (>60 y
of age) was related to a higher v-3 index (5.5§1.8) compared
with younger age (60 y of age, 7.1§2.1; P<0.001). v-3 supple-
ment users had a higher v-3 index compared with non-users
(P<0.001; Supplementary Table S3).
Fish consumption as dinner2 to 3 times per week was related
to a higher v-3 index (6.6§2.0) compared with less fish con-
sumption (5.5§2.1, P =0.019). An additional increase ofv-3 index
was found in patients having oily fish 1 to 3 times per week
(7.1§1.9, P =0.018). Patients with an v-3 index >8 were v-3 sup-
plement users and 83% of them had 2 to 3 weekly seafood serv-
ings as dinner.
Smoking was related to a lower v-3 index in current and for-
mer smokers (5.7) compared with never smokers (7.1, P =0.003).Table 4
Relative weight percentage of selected whole-blood FAs in RA patients and
grouped by disease activity (N=78)
Weight percentage of FA (wt%)
Total Remission Active RA P value
N=78 N=35 N=43
Saturated FA 37.5§1.9 38.0§2.1 37.3§1.8 0.15
Unsaturated FA 20.6§2.6 20.1§2.1 20.9§2.9 0.24*
Polyunsaturated FA 39.2§2.5 39.2§2.0 39.2§2.8 0.99
Sumv-6 FA 30.7§2.5 30.7§2.5 30.6§2.5 0.94
Sumv-3 FA 8.5§2.3 8.5§2.1 8.5§2.4 0.92*
v-3 index 6.2§2.1 6.2§2.0 6.2§2.2 0.98*
LA, 18:2 v-6 18.9§2.1 18.9§2.3 18.9§1.9 0.74*
AA, 20:4 v-6 9.3§1.4 9.2§1.3 9.3§1.5 0.98
ALA, 18:3 v-3 0.6§0.2 0.6§0.3 0.6§0.2 0.74*
EPA, 20:5 v-3 1.7§1.1 1.7§1.2 1.7§1.1 0.96*
DPA, 22:5 v-3 1.2§0.2 1.3§0.2 1.2§0.2 0.08
DHA, 22:6v-3 4.5§1.1 4.4§0.9 4.4§1.2 0.87*
AA, arachidonic acid; ALA, a-linolenic acid; DHA, docosahexaenoic acid; DPA,
docosapentaenoic acid; EPA, eicosapentaenoic acid; FA, fatty acid; LA, linolenic
acid; RA, rheumatoid arthritis; wt%, weight percentage of total FA.
Fatty acids (FAs) are reported as mean§ standard deviation in weight percentage
(wt%) calculated from total FA (wt%). Limit of quantification (LOQ) 0.1, values <0.1
were recoded to the half of LOQ.
Analyzed with Student t test.
*Analyzed with Wilcoxon rank-sum.Former smokers had an v-3 index of 0.03 higher than current
smokers (P = 0.96).
The relations of the different levels of v-3 index to selected FA,
total seafood intake, periodontal conditions and RA disease are
presented in Table 5.
Discussion
This study investigated marine v-3 and VitD levels, disease
outcome, and periodontal status in RA outpatients. Periodontitis
was more prevalent in RA patients seropositive for RF and/or
ACPA. The RA disease parameters MHAQ and VAS were lower in
females consuming seafood as recommended. The use of v-3 sup-
plement was associated with an v-3 index >8.
In the present study, females were approximately three times
more preponderant and appeared at a younger age than males
when diagnosed with RA. Previous reports confirm this finding,
describing a female dominance, especially in the premenopausal
age group. This relationship has been interpreted in terms of both
genetic and non-genetic risk factors [43].
Periodontitis was diagnosed in more than three-quarters of the
RA patients. Data from a meta-analysis have shown that RA
patients were more likely to have a higher prevalence and severity
of periodontitis than non-RA controls, and patients with periodon-
titis had a higher prevalence of RA than those without periodonti-
tis [5]. The prevalence of periodontitis in our group of RA patients
was almost twice as high for moderate and severe periodontitisAA, C20:4v-6 9.5§2.1 9.3§1.4 8.5§0.6
GLA; C20:3v-6 1.5§0.3 1.4§0.3 1.0§0.3 B,C
C18:1 20.6§3.0 18.0§2.0 A 16.1§1.4 B,C
C20:1 0.17§0.05 0.18§0.06 0.25§0.07 B,C
FFQ
Total seafood intake (g/d) 34§20 51§35 75§92
Periodontal data
PD (mm) 2.7§0.3 2.8§0.4 2.5§0.3 C
CAL (mm) 2.9§0.6 3.1§0.9 2.8§0.3
BoP (% of sites) 37§15 31§16 24§14
PI (% of sites) 38§10 32§18 32§13
RA data
RA duration, y 13§8 14§11 17§15
DAS28 (score) 3.2§0.9 2.9§1.2 3.2§1.1
VAS (score) 47§15 27§21 A 20§15 B
MHAQ (score) 0.60§0.41 0.35§0.39 0.31§0.23
Laboratory data
ESR (mm/h) 14§13 19§16 28§15 C
CRP (mg/L) 5§10 10§15 6§6
s-25(OH)D (nmol/L) 65§25 75§19 74§16
AA, arachidonic acid; BoP, bleeding on probing; CAL, clinical attachment level; CRP,
C-reactive protein; DAS28, disease activity score; ESR, erythrocyte sedimentation
rate; FA, fatty acid; FFQ, food frequency questionnaire; GLA, gamma-linolenic acid;
MHAQ, modified health assessment questionnaire; PD, probing depth; PI, plaque
index; RA, rheumatoid arthritis; s-25(OH)D, 25-hydroxyvitamin D; VAS, visual
analog scale; wt%, weight percentage of total FA.
Values reported as mean§ standard deviation. Analyzed with Student t test and
Wilcoxon rank-sum. Letters in superscript (A, B, and C) denote a significant differ-
ence (P<0.05) between thev-3 index groups: A v-3 index <4 versusv-3 index 4-
8; B v-3 index <4 versusv-3 index >8; Cv-3 index 4 to 8 versusv-3 index >8.
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lar diagnostic criteria for periodontitis [44]. Compared with an
epidemiologic study on oral health of inhabitants in J€onk€oping, a
Swedish city, the prevalence of periodontitis in RA patients in our
study was 2.6 times higher, and twice as many patients were diag-
nosed with severe periodontitis [45]. Importantly, the classifica-
tion systems applied were different in the studies. Overall, in our
study, applying the classification system by Eke et al. [32], severe
periodontitis was found in a slightly higher proportion than the
commonly reported range of 5% to 15% in any population [46].
Nevertheless, PD and CAL 4mm were identified in only 10% and
17% of the sites, respectively. The low number of sites with severe
periodontitis and narrow interindividual differences might be the
reason why we were not able to show differences for periodontal
measurements between active RA and remission.
Smoking and male sex have been reported as risk factors for
more severe periodontitis [44,46]. Accordingly, male smokers had
significantly higher mean PD and CAL compared with their respec-
tive counterparts. Furthermore, periodontitis worsened with age,
reflecting lifetime disease accumulation [46].
One of the strengths of this study is the performance of com-
prehensive periodontal measurements at site level including both
PD and CAL. Prevalence and severity estimates of periodontitis
depend on clinical assessment for periodontal measures and case
definitions used for periodontitis. The assessment of both PD and
CAL at six sites per tooth is the gold standard in clinical periodon-
tal examination to estimate the entire extent of periodontitis [44].
As a limitation and similar to the majority of the published stud-
ies, third molars were excluded to make our results best compara-
ble, but extent and severity of periodontitis may have been
underestimated [44].
Seropositivity to ACPA has been found to have a strong correla-
tion with RA disease severity [47] and is also associated with a
higher frequency of periodontitis compared with healthy controls
[5]. In the present study, patients seropositive to ACPA and/or RF
were significantly more frequently diagnosed with periodontitis.
Smoking is a major preventive risk factor for RA [48]. Especially
in seropositive patients, smoking has been found positively associ-
ated with the risk of RA [48,49]. In a Swedish population-based
case-control study, a dose-response association between cumula-
tive dose of smoking and risk of developing ACPA positive RA has
been observed [50]. In our study, a higher proportion of ACPA
seropositive patients were non-smokers, and fewer patients were
current smokers compared with seronegative patients. The high
number of never and former smokers in this study may explain
the inability to show significant differences between smoking sta-
tus and RA disease activity.
Seafood consumption was found at a high frequency in this group
of RA patients. This finding may be explained by a long tradition of
Norwegian seafood consumption. However, seafood consumption in
complete fulfilment of the Nordic nutrition recommendations (NNR)
[36] was found in only 35% of the patients. Comparing our data with
sex specific data from the latest national dietary survey (Norkost3)
[37], we found that daily fish consumption was 1.4 times higher in
male RA patients comparedwith females.
Females eating seafood at recommended frequency had better
health assessment (MHAQ and VAS) compared with females eat-
ing less seafood. This is in line with a previous study on fish con-
sumption in RA patients, where significantly lower disease
activity (DAS28) was observed in subjects consuming fish
2 times/wk compared to never or <1 time/mo fish intake [51].
The use of a validated FFQ questionnaire to estimate seafood
intake is a strength of this study. As a limitation, the FFQ is not
applicable to calculate v-3 supplement intake.The v-3 index is originally considered a risk stratification tool
for sudden cardiac death and has been used as a surrogate for
assessing tissue levels of EPA plus DHA [12]. An v-3 index >8 has
been considered as favorable, and an index of <4 may be regarded
as undesirable [42]. Oily fish and fish oil supplement are the pri-
mary source of EPA and DHA. Dose-response studies showed
increasing levels ofv-3 PUFA by increasing amount of fish oil sup-
plementation in a dose dependent manner [12]. In this study, all
patients having an v-3 index >8 were identified as v-3 supple-
ment users, and of them 83% had a seafood consumption in accor-
dance with NNR. Comparing our data with a study on FA
composition and presence of acute coronary syndrome in the US,
a group of Caucasian control patients showed an average 1.2 to
1.4 lower v-3 index [52]. These results may reflect the sparse fish
intake in the typical American diet. In Japan, a country with a
strong tradition of fish consumption and low prevalence of cardio-
vascular diseases, in older Japanese, an average v-3 index
between 8 and 10 was reported [53]. These findings are in accor-
dance with the data from our study, where the mean age was
highest for those with anv-3 index >8 and thev-3 index, ranging
from 9 to 13, was even higher than in the Japanese group. We
found that an v-3 index >8 was related to more desirable patient
global health assessment (VAS) and periodontal conditions com-
pared with a lower v-3 index. This v-3 group consisted of v-3
supplement users, exclusively. Our findings are consistent with
data of a prospective, randomized trial on fish oil supplementation
that showed decreased VAS and DAS28 compared with no supple-
mentation [54].
Another strength of this study is the performance of FA analy-
sis in whole-blood because the estimation of EPA and DHA intake
from seafood and/or v-3 supplement is thought to be difficult due
to differences in EPA and DHA content depending on season, the
fish's diet, and food preparation methods [52]. Conventionally,
FAs were measured in plasma or serum reflecting short-term fat
intake or in red blood cells (RBCs) reflecting long-term fat intake.
Whole-blood contains FAs from all lipid classes and reflects FA
status [55]. The EPA and DHA content of whole-blood samples,
which is used to calculate the v-3 index, was found to be highly
correlated with that of RBC [42].
According to the Norkost3 study, the VitD3 supplement intake
was 6.7mg/d in males and 4.9mg/d in females [37]. In our study,
the mean VitD3 supplement intake was higher in females com-
pared with males and higher compared with sex specific data
from Norkost3. Compared with the reference values for recom-
mended intake of VitD3 supplement, the intake in patients <75 y
in our study was twice as high in males and almost three times
higher in females [36]. Calcium supplementation containing VitD3
as a prophylactic adjuvant against osteoporosis in glucocorticoid
treatment and intake of v-3 supplement may reasonably explain
the higher intake in this patient group.
Assessing VitD status by measuring circulating s-25(OH)D is
generally considered as the best single marker of VitD status [40].
Currently, no general consensus on the required s-25(OH)D for an
adequate VitD status has been established. Some research indi-
cates that s-25(OH)D should be >50nmol/L [41], but other evi-
dence suggests s-25(OH)D levels >75nmol/L to cover both the
skeletal and non-skeletal benefits of VitD [56].
VitD status is reported to be higher in Northern Europe com-
pared with Southern Europe, despite higher latitude having
shorter periods of ultraviolet radiation from sun exposure [57].
Accordingly, in the present study 88% had an VitD status within
the recommended range and approximately half of them had s-25
(OH)D level of 75nmol/L. Norway's coastal location with strong
tradition of fatty fish and cod liver oil consumption may explain
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trations and RA disease activity and severity has been reported
[19], but this was not seen in the present study. The overall good
VitD status in this group of RA patients may explain the inability
to show differences for RA disease activity and periodontal diag-
nosis. Less intake of oily fish and lower/no VitD3 supplementation
was associated with lower VitD levels.
There are some limitations to the present study. The high per-
centage of low RA disease activity/remission and low prevalence
of deep periodontal pockets seen here may be the result of enroll-
ment taking place among patients attending a rheumatologic out-
patient clinic at a university hospital with a treat-to-target
treatment regime and good access to synthetic and biological
DMARDs. Furthermore, over the last 40 y, a continuous improve-
ment in oral health was seen, with increased number of individu-
als with no marginal bone loss and a decrease in the number of
subjects with moderate alveolar bone loss [45]. Good systematic
dental care, reflected by a high attendance rate and frequency of
dental recall visits as well as a high degree of self-performed oral
hygiene procedures may explain the overall low severity of peri-
odontitis (results not shown). On the other hand, the perceived
ability to pass through the examinations may have influenced the
patient's decision to participate in the study and may have
resulted in refusal by patients with more severe RA disease. The
RA disease treatment mode with synthetic and/or biological
DMARDs showed large interindividual differences resulting in
subgroups with few patients. The limited interindividual differen-
ces in outcome measurement of RA disease and periodontal dis-
ease, in addition to subgroups with small numbers of patients,
could be responsible for the inability to detect significant differen-
ces. The patient recruitment from urban catchment implies good
access to medical care as well as the earlier mentioned participa-
tion bias may challenge the validity and generalizability of the
results. Therefore, the results of this study should be evaluated
with caution due to the small sample size in the resulting groups.Conclusions
In this group of RA patients, the overall range of RA disease
activity was low, with a high percentage of patients in remission.
Despite this, periodontitis was more prevalent and severe in RA
patients and showed demographic and RA disease specific differ-
ences compared with what has previously been reported. The
prevalence of periodontitis was higher in seropositive versus sero-
negative patients. The use of v-3 supplement was related to a
higher v-3 index. An v-3 index >8 was associated with better RA
disease outcome. In general, RA patients in this study had a good
VitD status, which may explain the inability to show differences
for RA disease activity and periodontal diagnosis related to VitD.
A novelty of this study was the simultaneous assessment of RA
disease parameters, periodontitis measurements, marine v-3 sta-
tus by a FFQ and blood FA, and serum VitD levels in the same
group of patients. Longitudinal and interventional studies are
needed to further evaluate the effects of v-3 and VitD3 on RA and
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